Deutsche Bank
KLRA icon

Deutsche Bank’s Kailera Therapeutics KLRA Stock Holding History

Deutsche Bank’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$474K Sell
41,472
-4,176
-9% -$70.6K ﹤0.01% 2662
2026
Q2 		$1.01M Buy
+45,648
New +$1M ﹤0.01% 2358

Other funds holding KLRA

Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Royalty Pharma Sub-Manager
Royalty Pharma Sub-Manager New York $196M AUM 16.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Deutsche Bank's KLRA Position: Q3 2026 in Review

Deutsche Bank reduced its Kailera Therapeutics (KLRA) stake by 9.1% in Q3 2026, selling an estimated $70.6K and leaving 41,472 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Deutsche Bank first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.01M in Q2 2026. 82 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

  • Deutsche Bank held 41,472 shares of Kailera Therapeutics worth $474K as of Q3 2026.
  • Deutsche Bank sold 4,176 Kailera Therapeutics shares in Q3 2026, an estimated $70.6K.
  • Kailera Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2662 holding.
  • Deutsche Bank first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Deutsche Bank's Kailera Therapeutics position peaked at $1.01M in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.